AbbVie (NYSE: ABBV) has recently received a number of price target changes and ratings updates:

  • 10/2/2017 – AbbVie was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $106.00 price target on the stock, up previously from $89.00.
  • 10/1/2017 – AbbVie had its “neutral” rating reaffirmed by analysts at Credit Suisse Group. They now have a $94.00 price target on the stock, up previously from $74.00.
  • 9/30/2017 – AbbVie had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $100.00 price target on the stock, up previously from $95.00.
  • 9/29/2017 – AbbVie had its price target raised by analysts at Morgan Stanley from $70.00 to $95.00. They now have an “equal weight” rating on the stock.
  • 9/29/2017 – AbbVie had its price target raised by analysts at Argus from $90.00 to $110.00. They now have a “buy” rating on the stock.
  • 9/28/2017 – AbbVie had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $66.00 price target on the stock.
  • 9/28/2017 – AbbVie had its “hold” rating reaffirmed by analysts at Barclays PLC. They now have a $68.00 price target on the stock.
  • 9/28/2017 – AbbVie had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $107.00 price target on the stock.
  • 9/28/2017 – AbbVie had its price target raised by analysts at Deutsche Bank AG to $88.00. They now have a “hold” rating on the stock.
  • 9/25/2017 – AbbVie was downgraded by analysts at UBS AG from a “buy” rating to a “neutral” rating. They now have a $92.00 price target on the stock, up previously from $79.00. They wrote, “For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T),”
  • 9/15/2017 – AbbVie had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $100.00 price target on the stock.
  • 9/15/2017 – AbbVie had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $107.00 price target on the stock, up previously from $94.00.
  • 9/13/2017 – AbbVie had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $95.00 price target on the stock.
  • 9/12/2017 – AbbVie had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 9/11/2017 – AbbVie had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $95.00 price target on the stock, up previously from $70.00.
  • 9/8/2017 – AbbVie had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $94.00 price target on the stock.
  • 9/8/2017 – AbbVie had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $100.00 price target on the stock, up previously from $85.00.
  • 9/6/2017 – AbbVie was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/16/2017 – AbbVie is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $95.00 price target on the stock.

Shares of AbbVie Inc. (NYSE ABBV) opened at 89.70 on Wednesday. The stock has a market cap of $142.99 billion, a price-to-earnings ratio of 22.06 and a beta of 1.51. AbbVie Inc. has a 52 week low of $55.06 and a 52 week high of $90.95. The company has a 50-day moving average price of $80.54 and a 200-day moving average price of $71.50. AbbVie also was the target of some unusual options trading on Monday. Investors purchased 278 put options on the stock. This represents an increase of approximately 121% compared to the average daily volume of 126 put options.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. The firm had revenue of $6.94 billion for the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Equities analysts anticipate that AbbVie Inc. will post $5.52 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s dividend payout ratio is currently 62.90%.

In other news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $85.02, for a total value of $705,666.00. Following the transaction, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Robert A. Michael sold 6,699 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares in the company, valued at $880,616. The disclosure for this sale can be found here. Insiders have sold a total of 379,890 shares of company stock valued at $27,187,817 over the last three months. 0.23% of the stock is owned by corporate insiders.

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.